Skip to main content
SpringerLink
Log in
Book cover

Therapeutic Lipidology pp 55–68Cite as

Pathophysiology and Management of Dyslipidemias Associated with Obesity, Type 2 Diabetes, and Other Insulin-Resistant States

  • Chapter

  • 784 Accesses

Part of the book series: Contemporary Cardiology ((CONCARD))

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Reaven GM Syndrome X Past, present and future In: Draznrin B, Rizza R, eds. Clinical Research in Diabetes and Obesity, Vol. II: Diabetes and Obesity. Totowa, NJ: Humana Press, 1997;357–377.

    Google Scholar 

  2. Reaven GM Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease J Clin Endocrinol Metab 2003;88(6):6–2399.

    Google Scholar 

  3. Maki KC Dietary factors in the prevention of diabetes mellitus and coronary artery disease associated with the metabolic syndrome. Am J Cardiol 2004;93(Suppl):12C–17C.

    Article  PubMed  CAS  Google Scholar 

  4. Manson JE, Skerrett PJ, Greenland P, VanItallie TB The escalating pandemics of obesity and sedentary lifestyle A call for clinicians. Arch Intern Med 2004;164:249–258.

    Article  PubMed  Google Scholar 

  5. U.S. Department of Health and Human Services The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Available at http://www2.niddk.nih.gov/. (accessed October 8, 2006).

    Google Scholar 

  6. Reaven GM The metabolic syndrome: requiescat in pace Clin Chem 2005;51(6):6–931.

    Google Scholar 

  7. National Cholesterol Education Program Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults NIH Publication No 02-5215, 2002.

    Google Scholar 

  8. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment Circulation 1992;85:37–45.

    PubMed  CAS  Google Scholar 

  9. Ginsberg HN, Zhang Y, Hernandez-Ono A Regulation of plasma triglycerides in insulin resistance and diabetes Arch Med Res 2005;36:232–240.

    Google Scholar 

  10. Boden G Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver Curr Diab Rep 2006;6:177–181.

    Google Scholar 

  11. Bjorntorp P Visceral obesity: a “civilization syndrome”. Obes Res 1993;1:206–222.

    PubMed  CAS  Google Scholar 

  12. Sniderman AD, Cianflone K, Arner P, Summers LKM, Frayn KN The adipocyte, fatty acid trapping, and atherogenesis Arterioscler Thromb Vasc Biol 1998;18:147–151.

    PubMed  CAS  Google Scholar 

  13. Ginsberg HN, Zhang Y, Hernandez-Ono A Metabolic syndrome: focus on dyslipidemia Obesity 2006;14(Suppl):41S–49S.

    PubMed  CAS  Google Scholar 

  14. Packard CJ Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein Biochem Soc Trans 2003;31(Pt 5):1066–1069.

    PubMed  CAS  Google Scholar 

  15. Krauss RM Dense low density lipoproteins and coronary artery disease. Am J Cardiol 1995;75:53B–57B.

    Article  PubMed  CAS  Google Scholar 

  16. Austin MA, King MC, Vranizan KM, Krauss RM Atherogenic lipoprotein phenotype A proposed genetic marker for coronary heart disease risk Circulation 1990;82:495–506.

    PubMed  CAS  Google Scholar 

  17. Davidson MH, Bays HE, Stein E, Maki KC, Shalwitz RA, Doyle R Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects Clin Cardiol 2006;29:268–273.

    Article  PubMed  Google Scholar 

  18. Ginsberg HN Niacin in the metabolic syndrome: more risk than benefit? Nat Clin Pract Endocrinol Metab 2006;2:300–301.

    Article  PubMed  CAS  Google Scholar 

  19. Hu FB, Manson JE Walking. The best medicine for diabetes? Arch Intern Med 2003;163:1397–1398.

    Article  PubMed  Google Scholar 

  20. Maki KC Fibrates for treatment of the metabolic syndrome Curr Atheroscler Rep 2004;6:45–51.

    Article  PubMed  Google Scholar 

  21. Grundy SM Low-density lipoprotein, non-high-density liproprotein, and apolipoprotein, and apolipoprotein B as targets of lipid-lowering therapy Circulation 2002;106:2526–2529.

    Article  PubMed  Google Scholar 

  22. Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten country panel J Intern Med 2006;259:247–258.

    Article  PubMed  CAS  Google Scholar 

  23. Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003;361:777–780.

    Article  PubMed  CAS  Google Scholar 

  24. Grundy SM, Cleeman JI, Bairey CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation 2004;110:227–239.

    Article  PubMed  Google Scholar 

  25. Maki KC, Galant R, Davidson MH Non-high-density lipoprotein cholesterol: the forgotten therapeutic target Am J Cardiol 2005;96(Suppl):59K–64K.

    Article  PubMed  CAS  Google Scholar 

  26. Isaacsohn J, Hunninghake D, Schrott H, et al. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol 2003;26:18–24.

    Article  PubMed  Google Scholar 

  27. Watts GF, Barrett PH, Ji J, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome Diabetes 2003;52:803–811.

    Article  PubMed  CAS  Google Scholar 

  28. Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia Diabetes 2002;51:2377–2386.

    Article  PubMed  CAS  Google Scholar 

  29. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 2005;366:1267–1278.

    Article  CAS  Google Scholar 

  30. Katan MB, Grundy SM, Jones P, et al. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels Mayo Clin Proc 2003;78:965–978.

    Article  PubMed  CAS  Google Scholar 

  31. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia J Am Coll Cardiol 2002;40:2125–2134.

    Article  PubMed  CAS  Google Scholar 

  32. FIELD Investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 2005;366:1849–1861.

    Article  CAS  Google Scholar 

  33. BIP Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000;102:21–27.

    Google Scholar 

  34. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events VA-HIT: a randomized controlled trial JAMA 2001;285:1585–1591.

    Article  PubMed  CAS  Google Scholar 

  35. Ganji SH, Kamanna VS, Kashyap ML Niacin and cholesterol: role in cardiovascular disease (review). J Nutr Biochem 2003;14:298–305.

    Article  PubMed  CAS  Google Scholar 

  36. Kahn SE, Prigeon RL, Schwartz RS, et al. Obesity, body fat distribution, insulin sensitivity and islet beta-cell function as explanations for metabolic diversity J Nutr 2001;131:354S–360S.

    PubMed  CAS  Google Scholar 

  37. Chan DC, Watts GF, Mori TA, Barrett PH, Redgrave TG, Beilin LJ Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity Am J Clin Nutr 2003;77:300–307.

    PubMed  CAS  Google Scholar 

  38. Bays HE Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids Am J Cardiol 2006;98(4A):71i–76i.

    Article  PubMed  CAS  Google Scholar 

  39. Olefsky JM, Farquhar JW, Reaven GM Reappraisal of the role of insulin in hypertriglyceridemia Am J Med 1974;57(4):551–560.

    Article  PubMed  CAS  Google Scholar 

  40. Ginsberg HN Insulin resistance and cardiovascular disease J Clin Invest 2000;106(4):453–458.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Kevin C. Maki PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Director of Preventive Cardiology, Rush University Medical Center Radiant Research, Chicago, IL

    Michael H. Davidson MD,FACC,FACP

  2. Director of Preventive Cardiology, Sterling Rock Falls Clinic Chief of Medicine CGH Medical Center Clinical Associate Professor, University of Illinois College of Medicine, Peoria, IL

    Peter P. Toth MD,PhD,FAAP,FICA,FAHA,FCCP,FACC

  3. Southern Illinois University School of Medicine, Springfield, IL

    Peter P. Toth MD,PhD,FAAP,FICA,FAHA,FCCP,FACC

  4. Chief Science Officer,Provident Clinical Research, Bloomington, IN

    Kevin C. Maki PhD

  5. Weill Cornell Medical College, New York, NY

    Antonio M. Gotto Jr MD,DPhil

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc.

About this chapter

Cite this chapter

Maki, K.C. (2007). Pathophysiology and Management of Dyslipidemias Associated with Obesity, Type 2 Diabetes, and Other Insulin-Resistant States. In: Davidson, M.H., Toth, P.P., Maki, K.C., Gotto, A.M. (eds) Therapeutic Lipidology. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-59745-533-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-533-6_4

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-551-4

  • Online ISBN: 978-1-59745-533-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation